Adamis Pharmaceuticals Corporation
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2006-01-01
- Employees
- 131
- Market Cap
- -
Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients.
- First Posted Date
- 2021-01-28
- Last Posted Date
- 2022-12-06
- Lead Sponsor
- Adamis Pharmaceuticals Corporation
- Target Recruit Count
- 248
- Registration Number
- NCT04729595
- Locations
- 🇺🇸
Sunrise Research Institute, Sunrise, Florida, United States
🇺🇸Monroe Biomedical Research, Monroe, North Carolina, United States
🇺🇸Eastside Research Associates, Redmond, Washington, United States
Beclomethasone Dipropionate HFA in Adult and Adolescent Subjects With Mild to Moderate Persistent Asthma
Phase 3
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2019-02-11
- Last Posted Date
- 2019-07-17
- Lead Sponsor
- Adamis Pharmaceuticals Corporation
- Registration Number
- NCT03835871
Beclomethasone Dipropionate HFA in Adult and Adolescent Subjects With Persistent Asthma
Phase 3
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2019-02-07
- Last Posted Date
- 2019-07-17
- Lead Sponsor
- Adamis Pharmaceuticals Corporation
- Registration Number
- NCT03834012
Dose-Escalation and Safety Study of APC-100 for the Treatment of Prostate Cancer
- First Posted Date
- 2011-09-19
- Last Posted Date
- 2015-07-16
- Lead Sponsor
- Adamis Pharmaceuticals Corporation
- Target Recruit Count
- 60
- Registration Number
- NCT01436214
- Locations
- 🇺🇸
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
© Copyright 2024. All Rights Reserved by MedPath